PTC Therapeutics to Participate at Upcoming Investor Conferences

Nov 03, 2015, 16:06 ET from PTC Therapeutics, Inc.

SOUTH PLAINFIELD, N.J., Nov. 3, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced  that management will present a company update at the following conferences:

  • Credit Suisse 24th Annual Healthcare Conference, on Wednesday, November 11th at 8:30 a.m. MT at The Phoenician in Scottsdale, AZ
  • Stifel Nicolaus Healthcare Conference, on Wednesday, November 18th at 4:30 p.m. ET at the Palace Hotel in New York, NY

The presentations will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at and will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. PTC's current Investor Presentation and R&D Day slides are available at the same website location.

About PTC Therapeutics, Inc. PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA, or mRNA, molecule is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website

For More Information Please Contact:



Justine O'Malley

Emily Hill

+1 (908) 912-9551

+1 (908) 912-9327  


SOURCE PTC Therapeutics, Inc.